HONG KONG – A newly set up Japanese biotech is continuing the development of a potential first-in-class drug for the treatment of neuropathic pain associated with genetic mutations. The Kyoto-based firm, Alphanavi Pharma Co. Ltd., is a carve-out business venture from Sumitomo Dainippon Pharma Co. Ltd.